Phase II, open label clinical study to investigate anti-tumour effect and tolerability of the PARP inhibitor 2X-121 in patients with metastatic breast cancer selected by the 2X-121 DRP.
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2019
Price : $35 *
At a glance
- Drugs 2X 121 (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 17 Feb 2019 According to an Oncology Venture A/S media release, a first efficacy read-out from the breast cancer study of 2X-121 will be reported once patients have been treated long enough to demonstrate results.
- 26 Jun 2018 According to a Medical Prognosis Institute media release, the first patient has been dosed in the trial.
- 11 Mar 2018 Planned number of patients changed from 20 to 26.